Effort to screen potential COVID-19 antiviral drugs underway

Researchers can submit potential antiviral molecules for screening

Postdoctoral researcher Pallavi Chandra looks at plates containing cells infected with the COVID-19 virus in a biosafety level 3 laboratory as postdoctoral researcher Ekansh Mittal looks on. Chandra and Mittal are screening chemical compounds for their ability to inactivate the COVID-19 virus as part of an effort to find potential antiviral drugs. (Photo: Matt Miller/School of Medicine)

Six months into the pandemic, people diagnosed with mild cases of COVID-19 still are told to isolate themselves and wait out the infection at home. Doctors monitor such patients so they can intervene if their condition deteriorates, but no antiviral drugs have been shown to hasten recovery or forestall severe illness in people who are not sick enough to be hospitalized. Consequently, the hunt is still on for compounds that inactivate the COVID-19 virus and have potential to be developed as antiviral drugs.

A first step to finding antiviral drugs – before beginning studies in animals and people – is to screen chemical compounds for their ability to inactivate the virus in a dish. But many researchers don’t have access to high-security biosafety labs where they can work with a dangerous microbe like the COVID-19 virus. That’s where Jennifer A. Philips, MD, PhD, an associate professor of medicine and co-director of the Division of Infectious Diseases at Washington University School of Medicine in St. Louis, comes in. She has set up a screening platform to test compounds for activity against the COVID-19 virus. Her lab already has screened dozens of compounds suggested by 10 different researchers at Washington University and elsewhere, and is prepared to accept more suggestions of promising candidate molecules.

“In the beginning of the outbreak, a lot of people were screening compounds that are already approved by the FDA for other conditions and could be quickly repurposed to treat COVID,” said Philips, who is also an associate professor of molecular microbiology. “Now those screens have been done, and there are not a large number of promising candidates. So we’re still looking for more possibilities. There are so many scientists who may have insight into some aspect of cell biology related to their particular expertise that could be relevant to finding an antiviral for COVID, but they don’t necessarily have the expertise or the facilities to explore it. If they have a good reason for thinking a particular molecule might work against COVID, we can test it for them.”

The only antiviral drug authorized by the U.S. Food and Drug Administration to treat COVID-19 is remdesivir. The drug, which must be administered by IV, is only recommended for hospitalized patients and shortens the duration of illness by a few days. But many infectious disease experts think that an antiviral drug that could be given earlier in the course of the disease – while the virus is still multiplying rapidly and before a person becomes ill enough to need hospitalization – might be more effective at treating the disease.

Before the pandemic, Philips had not worked with viruses. Her lab focuses on tuberculosis, a bacterial lung infection. Since tuberculosis is a deadly airborne disease, researchers must work with the tuberculosis bacteria in a biosafety level 3 (BSL-3) laboratory, which is an enclosed area with multiple levels of containment and specialized ventilation systems to minimize the risk of exposure. The COVID-19 virus requires the same precautions, but many investigators do not have access to such a facility.

Realizing that she could help fight the pandemic by turning part of her BSL-3 space over to COVID-19 experiments, Philips reached out to Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine and an expert on viral infections, who already was working on COVID-19. Diamond’s lab members trained members of Philips’ lab in basic viral techniques and helped them set up a screening platform for chemical compounds known as small molecules. Now, with support from Washington University’s Institute of Clinical and Translational Sciences, the researchers are offering their services to the biomedical community at Washington University and elsewhere.

“Our intent is not to screen collections of thousands of compounds,” Philips said. “However, if someone suggests, say, a set of a few dozen compounds, we can do that. There has to be some biological plausibility and potential for development, but we don’t want to be too restrictive. In some cases, we’ve tested compounds that have been reported in the literature to have some activity, and we weren’t able to replicate those results. But that’s also helpful to know. You’d want to know if there is independent validation – or not – before doing further animal model testing or testing in people.”

To screen compounds, the researchers measure how many animal cells become infected when exposed to the virus, and whether adding the investigational compound reduces the number of infected cells. The researchers also assess whether the compound itself injures animal cells, since such toxicity would make a compound a poor candidate for a drug.

“We’ve found compounds that look promising for further optimization, and they have also now been identified in other screens, which is encouraging,” Philips said. “Given the ICTS funding, we have the capacity to screen more compounds now, so we’re hoping that more people will reach out to us with suggestions. We need to capture the ingenuity of the whole scientific community to defeat this virus.”

Investigators can submit requests for screening at this link.


This screening platform is supported by the Washington University Institute of Clinical and Translational Sciences (ICTS), grant number STAR112ICTS also is supported by grant UL1TR002345 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH).
Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Originally published by the School of Medicine

WashU Response to COVID-19
Visit coronavirus.wustl.edu for the latest information about WashU updates and policies. See all stories related to COVID-19.

Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.